Target intelligence / Profile preview

Methylcrotonoyl-CoA carboxylase subunit beta (MCCB)

Target
MCCB
Molecular classification
Enzyme, Carboxyltransferase, Mitochondrial protein
01

Overview

Methylcrotonoyl-CoA carboxylase subunit beta is the beta chain of the mitochondrial enzyme methylcrotonoyl-CoA carboxylase, which catalyzes the ATP-dependent biotin-requiring conversion of 3-methylcrotonoyl-CoA to 3-methylglutaconyl-CoA. This reaction represents the fourth step in the breakdown pathway for leucine, an essential branched-chain amino acid. The functional holoenzyme consists of six alpha and six beta subunits encoded by MCCC1 and MCCC2, respectively. Deficiency due to genetic mutations results in an inherited disorder characterized by impaired protein catabolism leading to toxic metabolite accumulation and clinical symptoms such as vomiting, metabolic acidosis, hypoglycemia, and low plasma carnitine levels. The enzyme plays a critical role in energy production from dietary proteins but is not currently considered a direct therapeutic drug target.

Other names
3-methylcrotonyl-CoA carboxylase beta chainMCCC2 (gene symbol)MCCBBeta subunit of methylcrotonoyl-CoA carboxylase
02

Biological functions

Amino acid catabolism (specifically leucine degradation)Energy metabolism (conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA)
03

Disease associations

Inborn error of metabolism (MCC deficiency / 3-methylcrotonyl-CoA carboxylase deficiency)Other metabolic disorders related to branched-chain amino acid breakdown
04

Safety considerations

Loss-of-function mutations cause metabolic acidosis, hypoglycemia, vomiting, and low plasma carnitine due to impaired leucine catabolism. There are no safety concerns related to pharmacological targeting since it is not currently targeted by drugs
05

Biomarkers

Accumulation of 3-hydroxyisovaleric acid and other metabolites in plasma/urine can serve as biomarkers for MCC deficiency.Low plasma carnitine levels may also be observed in affected individuals

Beyond the preview

Go deeper on Methylcrotonoyl-CoA carboxylase subunit beta (MCCB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methylcrotonoyl-CoA carboxylase subunit beta (MCCB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call